Straits Times Index
3,306.56 +13.63 (+0.41%) Nikkei
38,236.07 -38.03 (-0.10%) Hang Seng
18,497.49 +21.57 (+0.12%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
64,192.65 +819.21 (+1.29%) CMC Crypto 200
1,333.88 +56.90 (+4.46%)
Quoin Pharmaceuticals, Ltd. (QNRX)
After hours:
| Previous close | 0.7300 |
| Open | 0.7300 |
| Bid | 0.7420 x 100 |
| Ask | 0.8050 x 100 |
| Day's range | 0.7300 - 0.7950 |
| 52-week range | 0.6030 - 12.0000 |
| Volume | |
| Avg. volume | 653,103 |
| Market cap | 2.861M |
| Beta (5Y monthly) | 1.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024. The announcement will provide an operational update regarding the company’s achievements during the quarter, and will detail financial highlights. About Qu
- GlobeNewswire
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints Eligibility age for enrollment into both studies has been lowered to fourteen years and older No safety concerns have been observed to date in either ongoing clinical study Quoin expects its cash runway will extend into the second half of 2025 following $6.5 million offering on March 5th C
- GlobeNewswire
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024. The Company will host a conference call and webcast at 8:30am ET on Thursday, March 14, 2024. The call will include a discussion of fourth quart
